(Q34409787)

2 August 2017

title

Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial (English)

1 reference

2 August 2017

1 reference

0 references

1 reference

5

Carlos Vasconcelos

1 reference

2 August 2017

Ricard Cervera i Segura

16

object named as

Ricard Cervera

1 reference

2 August 2017

15

Loïc Guillevin

1 reference

2 August 2017

Frédéric A Houssiau

1

1 reference

2 August 2017

David D'Cruz

2

1 reference

2 August 2017

Shirish Sangle

3

1 reference

2 August 2017

Philippe Remy

4

1 reference

2 August 2017

Radmila Petrovic

6

1 reference

2 August 2017

Christoph Fiehn

7

1 reference

2 August 2017

Enrique de Ramon Garrido

8

1 reference

2 August 2017

Inge-Magrethe Gilboe

9

1 reference

2 August 2017

Maria Tektonidou

10

1 reference

2 August 2017

Daniel Blockmans

11

1 reference

2 August 2017

Isabelle Ravelingien

12

1 reference

2 August 2017

Véronique le Guern

13

1 reference

2 August 2017

Geneviève Depresseux

14

1 reference

2 August 2017

MAINTAIN Nephritis Trial Group

17

1 reference

2 August 2017

language of work or name

English

0 references

publication date

10 September 2010

1 reference

Annals of the Rheumatic Diseases

2 August 2017

published in

1 reference

2 August 2017

volume

69

1 reference

2 August 2017

issue

12

1 reference

2 August 2017

page(s)

2083-2089

1 reference

Mutagenicity and potential carcinogenicity of thiopurine treatment in patients with inflammatory bowel disease

2 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002764

Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002764

The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002764

Antifibrotic actions of mycophenolic acid

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002764

Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002764

Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002764

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002764

Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002764

Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002764

Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. II. Identification of the variables indicative of disease activity and their use in the development of an activ

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002764

Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002764

Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002764

Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002764

Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002764

Sequential therapies for proliferative lupus nephritis

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002764

Relapses of lupus nephritis: incidence, risk factors, serology and impact on outcome

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002764

Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002764

Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial

27 October 2018

1 reference

12 December 2020

Preventing cardiac allograft vasculopathy: long-term beneficial effects of mycophenolate mofetil

1 reference

12 December 2020

Reviewing the evidence for mycophenolate mofetil as a new teratogen: Case report and review of the literature

1 reference

12 December 2020

Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group

1 reference

12 December 2020

Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs

1 reference

12 December 2020

Identifiers

DOI

10.1136/ARD.2010.131995

1 reference

release_crfn52bsenfhzfjpw7cpmx3vjy

2 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/crfn52bsenfhzfjpw7cpmx3vjy

24 November 2022

mapped directly with Wikidata item

PMC publication ID

3002764

1 reference

2 August 2017

1 reference